<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332025000200078</article-id>
<article-id pub-id-type="doi">10.24875/rccar.24000056</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto en los desenlaces intrahospitalarios con el inicio de un inhibidor del cotransportador de sodio-glucosa 2 (iSGLT2) en insuficiencia cardíaca aguda descompensada]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact on in-hospital outcomes with the initiation of a sodium-glucose cotransporter 2 inhibitor (iSGLT2) in acute decompensated heart failure]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Martínez]]></surname>
<given-names><![CDATA[Wilfredo A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mejía-Cardona]]></surname>
<given-names><![CDATA[Andrés F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Solarte]]></surname>
<given-names><![CDATA[Aura Ma.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aristizábal-Colorado]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcés-Villabón]]></surname>
<given-names><![CDATA[Leopoldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinillos-Sénior]]></surname>
<given-names><![CDATA[Óscar M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampo-Posada]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4 "/>
<xref ref-type="aff" rid="Af5"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Facultad de Medicina Servicio de Endocrinología]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Libre Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Libre Grupo interinstitucional Medicina Interna (GIMI 1) ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Clínica Versalles Cali S.A Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad Javeriana Grupo de Investigación en Ciencias Básicas y Clínicas de la Salud ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<volume>32</volume>
<numero>2</numero>
<fpage>78</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332025000200078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332025000200078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332025000200078&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: los inhibidores del cotransportador de sodio-glucosa 2 (iSGLT2), inicialmente usados en el manejo de la diabetes mellitus tipo 2, también han demostrado eficacia en insuficiencia cardíaca crónica (ICC) sintomática, independientemente de la fracción de eyección del ventrículo izquierdo (FEVI). Su uso temprano en insuficiencia cardíaca aguda podría impactar los desenlaces durante la estancia hospitalaria.  Objetivo: evaluar el impacto en los desenlaces intrahospitalarios tras el inicio temprano de un iSGLT2 en pacientes con insuficiencia cardíaca aguda descompensada con FEVI reducida.  Materiales y método: estudio de cohorte retrospectiva a partir del registro MALEOS, en el que se seleccionaron pacientes con insuficiencia cardíaca aguda descompensada, con FEVI &#8804; 40%, sin uso previo de iSGLT2. Se clasificaron de manera retrospectiva según el inicio o no de iSGLT2 durante el ingreso hospitalario. El resultado final evaluado fue compuesto por: muerte, estancia hospitalaria prolongada (&gt; 21 días) o requerimiento de uso de inotrópicos. Se realizó un análisis por regresión de COX y los resultados se resumieron con el uso de las curvas de supervivencia de Kaplan-Meier.  Resultados: se captaron 173 pacientes en total; a 53 se les inició un iSGLT2. El uso de iSGLT2 redujo en un modelo de ajuste multivariado el resultado combinado (5/37), comparado con quienes no lo recibieron (48/136), HR 0.37 (IC 95%: 0.12-0.45; p = 0.009). El resultado fue menos frecuente en quienes, además, recibían un antagonista del receptor de neprilisina (ARNI) o un betabloqueador.  Conclusiones: la adición intrahospitalaria de un iSGLT2 al tratamiento de pacientes con insuficiencia cardíaca aguda descompensada con FEVI &#8804; 40%, mejoró los desenlaces primarios ya que redujo la estancia hospitalaria y mejoró la supervivencia hasta el alta.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially used in the management of type 2 diabetes mellitus, have also demonstrated efficacy in symptomatic chronic heart failure (CHF) regardless of left ventricular ejection fraction (LVEF). Its early use in acute heart failure could have an impact on outcomes during the hospital stay.  Objective: to assess the impact on in-hospital outcomes after early initiation of an SGLT2 inhibitor in patients with acute decompensated heart failure with reduced LVEF.  Materials and method: it is a retrospective cohort taken from the MALEOS registry, in which patients with acute decompensated heart failure, with LVEF &#8804; 40%, and without prior use of SGLT2i were selected and retrospectively classified according to whether or not they started SGLT2i during hospital admission. The final outcome was a composite of death, prolonged hospital stay (&gt; 21 days), or requirement for inotropic use. COX regression analysis was performed and results were summarized using Kaplan-Meier survival curves.  Results: a total of 173 patients were recruited, 53 were started on an SGLT2i. The use of SGLT2i reduced the composite outcome in a multivariate adjustment model (5/37), compared to those who did not receive it (48/136), HR 0.37 (95% CI 0.12-0.45, p 0.009). The result was less frequent in those who also received a Neprilysin receptor antagonist (ARNI) or a beta blocker.  Conclusions: the in-hospital addition of an SGLT2i to treatment, in patients with acute decompensated heart failure with LVEF &#8804; 40%, resulted in an improvement in primary outcomes, with a reduction in hospital stay and improved survival to discharge.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insuficiencia cardíaca]]></kwd>
<kwd lng="es"><![CDATA[Hispanos]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad aguda]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores del cotransportador de sodio-glucosa 2]]></kwd>
<kwd lng="es"><![CDATA[Mortalidad]]></kwd>
<kwd lng="es"><![CDATA[Tiempo de internación]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Acute disease]]></kwd>
<kwd lng="en"><![CDATA[Sodium-glucose transporter 2 inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Mortality]]></kwd>
<kwd lng="en"><![CDATA[Length of stay]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farmakis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Parissis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lekakis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute heart failure:Epidemiology, risk factors, and prevention]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<page-range>245-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Formiga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Corbella]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Martel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Llácer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Rocha]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De novo acute heart failure:Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2019</year>
<volume>152</volume>
<page-range>127-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bavishi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Freaney]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart Failure risk distribution and trends in the United States population, NHANES 1999-2016]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2021</year>
<volume>134</volume>
<page-range>e153-64</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Mozaffarian]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Blaha]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics-2014 update:a report from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>129</volume>
<page-range>e28-292</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of heart failure and scope of the problem]]></article-title>
<source><![CDATA[Cardiol Clin]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsiao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary treatment of acute heart failure]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2016</year>
<volume>58</volume>
<page-range>367-78</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Fonarow]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Stough]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Gheorghiade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of in-hospital mortality in patients hospitalized for heart failure:insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2008</year>
<volume>52</volume>
<page-range>347-56</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Hasselblad]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Tasissa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Califf]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Fiuzat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triage after hospitalization with advanced heart failure:the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>872-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunlay]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Weston]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Therneau]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Hall Long]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospitalizations after heart failure diagnosis a community perspective]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2009</year>
<volume>54</volume>
<page-range>1695-702</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Byun]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Colvin]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>79</volume>
<page-range>e263-421</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomcikova]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Felsoci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Spinar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Miklik]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mikusova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vitovec]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of in-hospital mortality identified according to the typology of patients with acute heart failure:classification tree analysis on data from the Acute Heart Failure Database-Main registry]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>250-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Rouleau]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Naimark]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting mortality among patients hospitalized for heart failure:derivation and validation of a clinical model]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>290</volume>
<page-range>2581-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauersachs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure drug treatment:the fantastic four]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<page-range>681-3</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Angermann]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Teerlink]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Biegus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure:a multinational randomized trial]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2022</year>
<volume>28</volume>
<page-range>568-74</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Bocchi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin in heart failure with a preserved ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<page-range>1451-61</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and renal outcomes with empagliflozin in heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>1413-24</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Szarek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sotagliflozin in patients with diabetes and recent worsening heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>117-28</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ocampo-Posada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aristizabal-Colorado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Martinez]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Valderrama-Teran]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mejia-Cardona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garces-Villabon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registry of acutely decompensated heart failure in a clinic in Cali, Colombia (MALEOS)]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2024</year>
<volume>31</volume>
<numero>supl 2</numero>
<issue>supl 2</issue>
<page-range>103:254</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaprutko]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Michalak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nowicka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dankowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dro&#380;d&#380;]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospitalisation length and prognosis in heart failure patients]]></article-title>
<source><![CDATA[Kardiol Pol]]></source>
<year>2017</year>
<volume>75</volume>
<page-range>323-31</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Skali]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>116</volume>
<page-range>1482-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with heart failure and reduced ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>1995-2008</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Beusekamp]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Boorsma]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Swart]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Smilde]]></surname>
<given-names><![CDATA[TDJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elvan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2020</year>
<volume>22</volume>
<page-range>713-22</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors in patients with heart failure with reduced ejection fraction:a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2020</year>
<volume>396</volume>
<page-range>819-29</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biegus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Teerlink]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Angermann]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of empagliflozin on decongestion in acute heart failure:the EMPULSE trial]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2023</year>
<volume>44</volume>
<page-range>41-50</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velazquez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[DeVore]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrosy]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[McCague]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin-Neprilysin inhibition in acute decompensated heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<page-range>539-48</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Senni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wachter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Witte]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Straburzynska-Migaj]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Belohlavek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure:a subgroup analysis of the TRANSITION study]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2020</year>
<volume>22</volume>
<page-range>303-12</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wachter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Senni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Belohlavek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Straburzynska-Migaj]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Witte]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Kobalava]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge:primary results of the randomised TRANSITION study]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2019</year>
<volume>21</volume>
<page-range>998-1007</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aristizábal-Colorado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo-Posada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Martínez]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors and how they work beyond the Glucosuric effect. State of the art]]></article-title>
<source><![CDATA[Am J Cardiovasc Drugs]]></source>
<year>2024</year>
<volume>24</volume>
<page-range>707-18</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aristizábal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[JMH]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reconociendo la congestión en insuficiencia cardíaca aguda, terapéuticas del primer mundo adaptadas para el tercer mundo]]></article-title>
<source><![CDATA[Interdiscip J Epidemiol Public Health]]></source>
<year>2022</year>
<volume>5</volume>
<page-range>e-9904</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure:Key insights into ADVOR and EMPULSE]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2023</year>
<volume>25</volume>
<page-range>1537-43</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Tomlinson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caesar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How much do operational processes affect hospital inpatient discharge rates?]]></article-title>
<source><![CDATA[J Public Health Oxf Engl]]></source>
<year>2009</year>
<volume>31</volume>
<page-range>546-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
